BenevolentAl Therapeutics Pipeline and Triage
Atopic Dermatitis (AD)
• Atopic dermatitis is the most common chronic
inflammatory skin disease, characterized by intensely
itchy, red, and swollen skin
o Affects 10-20% of children and up to 3% of adults (1)
o Approximately 60-70% of all cases present with
mild-moderate disease severity (2)
○ Prevalence is rising, with market value in 7MM
forecast to exceed $14 billion by expected launch
of BEN-2293 in 2028 (1)
• Skin inflammation and chronic pruritus associated with
atopic dermatitis negatively impact quality of life and
psychosocial well-being
Clear unmet need in mild to moderate patient segment
for treatment addressing itch and inflammation, without
side effects of steroids
BEN-2293: A potent PanTrk antagonist
developed to relieve inflammation and provide
rapid itch resolution in patients with AD
•
BEN-2293 is a PanTrk inhibitor targeting TrkA, B and C
receptors. The Trk receptors were identified as part of an
effort to find mediators of both itch and inflammation in
AD. Using our Molecular Design expertise we were able to
design a PanTrk inhibitor, equipotent against the 3
receptors
BEN-2293 is expected to treat atopic dermatitis by:
Inhibiting itch signaling and blocking nerve sensitization
(TrkA) in addition to inhibiting Thl and Th2-mediated
dermal inflammation (TrkB, TrkC)
BEN-2293 will target Mild, Moderate and Severe Atopic
Dermatitis patients, addressing unmet need in the
treatment of mild to moderate Atopic Dermatitis as a
steroid sparing alternative and in more severe patients
undergoing treatment with biologics (e.g. dupilumab)
that require add-on treatment
Source: (1) GlobalData - Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027;
Evaluate Pharma - Eczema/Dermatitis: Worldwide Sales 2026 (2) GlobalData - Atopic Dermatitis:
Epidemiology Forecast to 2027
Benevolent 65
ΑΙ
HPA-Hypothalamus, Pituitary, AdrenalView entire presentation